Bridged piperidine derivatives

Abstract

The present invention relates to a compound of formula wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R 1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R 2 is lower alkyl substituted by halogen, —CH 2 —C 3-6 -cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; R 3 is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C 3-6 -cycloalkyl or lower alkyl substituted by hydroxy; n is 1 or 2; for n=2, R 1 can be independent to each other; Y is CH or N; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

1 . A compound of formula 
       
         
           
           
               
               
           
         
         wherein 
         HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; 
         R 1  is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; 
         R 2  is lower alkyl substituted by halogen, —CH 2 —C 3-6 -cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; 
         R 3  is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C 3-6 -cycloalkyl or lower alkyl substituted by hydroxy; 
         n is 1 or 2; for n=2, R 1  can be independent to each other; 
         Y is CH or N; 
         or a pharmaceutically active acid addition salt thereof, racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
       
     
     
         2 - 31 . (canceled)